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Abstract
Adeno-associated viral vectors, which are undergoing broad exploration in clinical trials, have 
significant promise for therapeutic gene delivery due to their safety and delivery efficiency. Gene 
delivery technologies capable of mediating localized gene expression may further enhance AAV’s 
potential in a variety of therapeutic applications by reducing spread outside of a target region, 
which may thereby reduce off-target side effects. We have genetically engineered an AAV variant 
capable of binding to surfaces with high affinity via a hexahistidine-metal binding interaction. 
This immobilized AAV vector system mediates high efficiency delivery to cells that contact the 
surface and thus may have promise for localized gene delivery, which may aid numerous 
applications of AAV delivery to gene therapy.
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Introduction
Adeno-associated virus is a non-pathogenic parvovirus that depends on the presence of a 
helper virus, such as adenovirus, to replicate. It has a single-stranded 4.7-kb genome 
contains two open reading frames (ORFs), rep and cap, which encode proteins that mediate 
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replication of the viral genome and form the viral capsid, respectively. Recombinant AAV 
vectors, in which a transgene is inserted in place of the viral genome, have the capacity to 
deliver genes to both dividing and non-dividing cells in numerous tissues, such as muscle 1, 
brain 2, and retina 3. Furthermore, AAV has enjoyed recent clinical success, including in 
clinical trials that employed AAV2-mediated gene delivery to the retina for the treatment of 
Leber’s congenital amaurosis and resulted in significant improvements in sight for numerous 
patients 4, 5. Despite these numerous advantages, a number of challenges remain in 
engineering AAV gene delivery systems, such as achieving targeted and/or localized gene 
delivery to specific cells and tissues.
Gene delivery typically involves the direct injection of a vector in solution; however, this 
mode of administration is accompanied by its local or systemic spread away from the 
injection site 6. Such spreading can reduce vector levels at the target site, lead to possible 
side effects in off-target regions, and potentially enhance immune responses against the 
vector. As an alternative, immobilizing gene delivery vectors onto material surfaces 
followed by implantation into target regions, i.e. substrate-mediated gene delivery, is a 
strategy that can potentially yield effective and localized gene expression while preventing 
systemic vector spread 7, 8. Specifically, substrate-mediated delivery places the vectors into 
sustained contact with target cells to facilitate subsequent cellular internalization, and in 
some systems it has been shown to overcome mass transfer barriers or limitations to gene 
transfer 9. Additionally, substrate-mediated delivery has the potential to reduce the vector 
quantities required for high level gene expression, and in the cases of adenoviral vectors and 
non-viral vehicles, the use of lower doses in substrate-mediated delivery can result in 
reduced cellular toxicity, which is typically caused by the initial burst of vector upon direct 
injection in vivo 10–12. Due to these advantages, a variety of substrate-mediated gene 
delivery systems have been employed, primarily involving non-viral vectors and 
biomaterials 12, 13. Although viral vectors can have significantly higher gene transfer 
efficiencies than non-viral vectors, few studies have investigated viral vector delivery from 
substrates, presumably due to the lack of moieties on the viral surfaces that can specifically 
interact with biomaterials compared to engineered non-viral vectors 8, 14–16. However, 
developing substrate-mediated delivery approaches for viral vectors may yield systems that 
combine cell contact-mediated delivery with high efficiency. Due to an increasing 
understanding of its capsid, AAV vectors have the potential to be readily modified to 
interact with a substrate, thereby mediating “localized” AAV delivery to cells that come into 
contact with the substrate.
Results and Discussion
We have developed a strategy to specifically immobilize AAV vectors directly onto a 
substrate to which cells subsequently adhere, thus concentrating the virus for direct contact 
with the cell. Specifically, we had previously inserted a hexa-histidine (6xHis) onto a 
physically-exposed loop of the AAV2 (i.e., amino acid 587 position) (Figure 1a) and AAV8 
capsids, which enabled an efficient, single step viral purification via immobilized metal 
affinity chromatography (IMAC) 17. The resulting tagged virus was able to mediate high 
efficiency gene delivery in vivo and elicited a macrophage and T-cell immune response 
equivalent to that of a phosphate buffer control injection 17. Here, the same 6xHis tag was 
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harnessed to immobilize AAV onto a material surface that presents nickel ions chelated by 
biotin-nitrilotriacetic acid (biotin-NTA) moieties bound to a streptavidin-coated surface 
(Figure 1b). Once the AAV vectors were bound to the surface, various cell types – including 
HEK293T, CHO, HeLa, and B16F10 cells – were plated on these substrates, and the 
subsequent gene delivery was analyzed and compared to gene expression achieved via the 
direct addition (i.e., bolus delivery) of AAV vector (with either wild type AAV2 or 6xHis 
tag capsids) to the cell culture medium.
The presence of histidine residues on each of 60 capsid protein subunits likely leads to the 
binding of a single virus to multiple Ni-NTA groups, resulting in potentially strong 
multivalent binding to the surface 18. Tuning virus binding levels and strength could thus 
potentially optimize downstream transduction.
To modulate the interactions between histidine residues and multiple Ni-NTA groups, 
chimeric 6xHis-AAV vectors were generated by mixing AAV packaging plasmids encoding 
the 6xHis mutant (pXX2 His6) or the wild type capsid 2 (pXX2Not) at various mass ratios 
(i.e., 100%, 75%, 50%, 25%, and 0% (w/w) pXX2 His6). In the case of 100% pXX2 His6 
plasmid, all sixty viral protein subunits would display histidine residues on the capsid 17, 
and as the proportion of pXX2 His6 is reduced, the number of 6x histidine residues exposed 
on the viral shells is anticipated to decrease (Figure 2a) 19. This reduced presence of 
histidine tags on the virus likely decreases the extent of multivalent interaction between a 
single vector and Ni-NTA, thereby decreasing the overall affinity of the virus for the 
surface. We anticipate that the capsids should contain sufficient levels of histidine to 
become effectively immobilized to the surfaces; however, overly strong interactions may 
inhibit subsequent vector release from the surface and thereby reduce gene delivery. 
Therefore, low or intermediate histidine levels should both adsorb effectively and 
subsequently be released in close proximity to adjacent cell surfaces to mediate gene 
delivery. It is also possible that the binding of the immobilized virus to its cellular receptors 
may aid vector desorption from the surface.
We first analyzed the extent of AAV immobilization to surfaces as a function of histidine 
content. Interestingly, low levels of 6xHis in the vector resulted in effective AAV 
immobilization to the surface, and the amount of bound virus decreased with increasing 
histidine. That is, maximal surface binding occurred for vectors packaged with 25% of 
6xHis and 75% wild type AAV2 capsid helper plasmids (i.e., 25% 6xHis AAV vectors, 
Figure 2b). The reduced binding with higher levels of 6xHis may be due to free capsid 
proteins not incorporated into viral particles competing with assembled capsids for binding 
to the surface. In addition to modulating the capsid, changing the concentration of biotin-
NTA on the streptavidin substrate was a major factor that modulated the amount of 
immobilized 6xHis AAV vector (Figure 2b). Viral binding increased substantially as the 
level of biotin-NTA was elevated up to 10 pmol, but higher concentrations of biotin-NTA 
(i.e., 100, 1000 pmol) did not further enhance AAV binding. This binding saturation at 10 
pmol was observed for all 6xHis AAV formulations. The increased viral binding with higher 
biotin-NTA levels may be due to a progressive increase in the number of sterically 
accessible NTA groups for the virus to bind.
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The capacity for localized gene delivery to cells that come into contact with a vector-loaded 
substrate vector requires that the surfaces not prematurely release the vector. To assess 
desorption in the absence of cells, we incubated the AAV-laden substrates with cell-culture 
medium. Approximately 6–14% of bound vector initially dissociated from the surface, but 
for the subsequent 6 days no additional vector desorbed under any conditions (Figure 2c). 
To investigate the extent to which cells internalize virus introduced by direct addition vs. 
substrate-mediated delivery, cell-internalized AAV vector was quantified as a function of 
time and the concentration of biotin-NTA after plating HEK293 cells on the virus using a 
previously published approach 20. Approximately 15–20% of the surface-bound 6xHis 
AAV vector was associated with cells by 2 days, and the level progressively increased 
through day 6 (Figure 3a). In contrast, the majority of wild type AAV2 vector and 25% 
6xHis AAV vector directly added to the medium was internalized into cells within 2 days of 
exposure to HEK293T (Figure 3a). The difference in cellular internalization between 
wtAAV2 and 25% 6xHis AAV upon direct addition may represent differences in the 
affinities of each vector for cell surface receptors, presumably heparan sulfate proteoglycans 
(HSPG) 21, as our previous study indicated that insertion of 6x histidine into aa587 resulted 
in a slightly reduced affinity for a heparin column compared with wtAAV2 17. Regardless, 
the cellular internalization results for the immobilized vector importantly indicate cell 
contact with the bound vector can lead to localized vector uptake.
To analyze substrate-mediated gene delivery, 293 cells were incubated on surfaces bound 
with AAV at a number of 6xHis formulations, and after 2 days luciferase gene expression 
was assayed. The 25% 6xHis formulation, which yielded optimal vector binding to the 
surface (Figure 2a), resulted in the highest substrate-mediated gene expression. This result 
indicates that the binding capacities of the 6xHis AAV vector are likely an important 
determinant of gene delivery efficiency (Figure 3b)
We next analyzed whether surface-immobilized AAV could mediate transduction of several 
additional cell types, including CHO, HeLa, and B16F10 cells. HEK293T and HeLa cells, 
which are highly permissive to AAV2, were utilized as positive controls, and Chinese 
hamster ovary (CHO) cells and B16F10 human melanoma cells were chosen to assess 
delivery to cells known to be non-permissive to AAV2. Infection with AAV carrying a 
luciferase reporter gene varied as a function of both the levels of histidine residues in the 
vector and biotin-NTA on the surface, demonstrating the potential for modulating localized 
gene delivery though engineering and tuning the virus-substrate interactions. Luciferase 
gene expression following bolus vs. substrate-mediated delivery of 25% 6xHis AAV and 
wtAAV2 was examined at day 2, 4, and 6. Note that, to enable a comparison with bolus 
delivery, the level of AAV directly added to the medium was fixed at 1 × 107 viral genomes, 
equal to the levels of vector immobilized to the substrate prior to addition of cells based on 
viral binding results (Figure 2).
The onset of gene expression following bolus infection was more rapid and could be 
detected by 2 days; however, luciferase expression mediated by substrate-mediated delivery 
reached that of bolus delivery over time (Figure 4). Substrate-mediated delivery to 293 cells 
demonstrated similar or slightly improved gene transfer capabilities as compared with direct 
addition method. One interesting and important aspect of this substrate-mediated delivery is 
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that comparable gene expression could be obtained even with significantly reduced 
quantities of internalized vector as compared with bolus delivery (~70% less in Figure 3a), 
indicating that substrate-mediated delivery may somehow alter intracellular processing of 
the vector. In addition to 293 cells, substrate-mediated delivery to HeLa and CHO cells was 
comparable or slightly reduced compared to bolus delivery. Finally, delivery to B16F10 
cells, a human melanoma cell line reported to be non-permissive to AAV transduction 22, 
was equivalent or slightly higher for substrate-mediated delivery vs. bolus addition.
In conclusion, this study developed a novel AAV delivery system to mediate local gene 
delivery, with comparable gene transfer efficiency to a bolus delivery for a variety of cell 
types. Since one possible rate limiting step for AAV transduction is limitations in binding to 
the cell surface, we hypothesized that maintaining high local concentration of AAV vectors 
within the cell microenvironment, as well as increasing the physical contact time with the 
target cell types, may be a promising approach to mediate localized and efficient AAV 
vector gene delivery. Importantly, this system yielded comparable gene expression with 
significantly reduced internalized viral quantities compared to bolus or direct addition to 
medium. Furthermore, we anticipate that the level of gene expression can be tuned by 
controlling binding capacities (e.g., bound quantity, strength of binding, etc.), which implies 
that “smart” gene delivery devices can be developed for controlled release of vector. Finally, 
since the substrate can be potentially “upgraded” to three dimensional scaffolds, this system 
may have future application in tissue engineering and regenerative medicine efforts. The 
AAV vector can be incorporated into such a material or device as the final step, such that 
complex scaffold fabrication processes would not affect the activity of surface-bound AAV. 
The development of systems with the capacity for local, efficient gene transfer therefore 
represents an additional gene delivery mode with the potential for application to a number of 
disease therapies.
Materials and Methods
Cell culture
HEK293T and B16F10 were cultured in Dulbecco’s modified Eagle medium (DMEM; 
Mediatech, Herndon, VA), HeLa in Iscove’s modified Dulbecco’s medium (IMDM, 
Mediatech, Herndon, VA), and CHO in DMEM/F-12 (1:1) (Invitrogen) with 10% fetal 
bovine serum (FBS) (Invitrogen, Carlsbad, CA) and 1% penicillin and streptomycin 
(Invitrogen) at 37°C and 5% CO2. All cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA). For viral packaging, AAV293 cells (Stratagene, 
La Jolla, CA) were grown in DMEM with 10% FBS and 1% penicillin and streptomycin at 
37°C and 5% CO2.
Production and purification of 6xHis AAV vectors
Construction of 6x-histidine coding plasmids (pXX2 His6) and pXX2Not are described in a 
previous study 17, and histidine residues were inserted at 587 amino acid sequence, 
corresponding to physically exposed loop domain: - LQRGNLGHHHHHHSRQA- (wt 
AAV2: 583LQRGNRQA-). Hexa-histidine-AAVs (6x His-AAV) were packaged with 
variable total mass ratios of 6x-histidine coding plasmids to pXX2Not. Recombinant AAV 
Jang et al. Page 5
Gene Ther. Author manuscript; available in PMC 2011 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
encoding luciferase was produced by methods described in a study 23. Briefly, viral vectors 
were packaged using calcium-phosphate transient transfection of pAAV CMV luc, pHelper, 
pXX2Not, and pXX2 His6, and were harvested as previously described 24. The levels of 
hexahistidine-presenting capsid proteins within a preparation were changed by varying the 
relative amounts of pXX2 His6 and pXX2Not: 100% (7 µg: pXX2His6, 0 µg: pXX2Not), 
75% (5.25 µg: 1.75 µg), 50% (3.5 µg: 3.5 µg), 25% (1.75 µg: 5.25µg), and 0% (0 µg: 7 µg). 
Subsequently, 1 volume of cell lysate was mixed with 0.5 volume of binding buffer (10 mM 
Tris [pH 8.0], 300 mM NaCl, and 20 mM imidazole) and 500 µL of 50% Ni-NTA agarose 
beads (Qiagen, Valencia, CA). This mixture was agitated gently overnight at 4°C, then 
loaded onto a plastic column (Kontes, Vineland, NJ). The loaded mixture was washed twice 
with 5 mL of wash buffer (10 mM Tris [pH 8.0], 50 mM imidazole), and viral vectors bound 
to the Ni-NTA beads were eluted with 2–3 mL of elution buffer (10 mM Tris [pH 8.0], 500 
mM imidazole). The eluted virus was then concentrated using Microcon spin columns 
(Millipore, Billerica, MA) according to the manufacturer’s instructions and buffer 
exchanged into phosphate-buffered saline (PBS) / 0.01% Tween.
Immobilization of 6xHis AAV vectors
Hexa-Histidine-tagged AAV vectors were immobilized onto the surface by varying the 
concentration of biotin-NTA and the quantity of histidine residues on the viral surfaces. 
Prior to immobilizing the 6xHis AAV vectors, the streptavidin-coated polystyrene surfaces 
(Roche, Pleasanton, CA) were pre-washed with PBS/0.01% Tween according to the 
manufacturer’s instructions, and a mixture (100 µL) of nickel chloride (100 mM) with 
biotin-NTA (0, 0.1, 1, 10, 100, 1000 pmol) was agitated gently on the surface at room 
temperature for 4 hours. The surface was then washed three times with PBS/0.01% Tween 
to remove unbound Ni-NTA-biotin. Finally, purified viral vector (107 genomic particles) 
was added onto the surface and agitated gently at 4°C overnight. The surface was rinsed 
three times with PBS/0.01% Tween to remove unbound AAV, and each cell type (5,000 
cells/well, 200 µL) was then seeded onto the surface.
Quantification of surface-bound and dissociated AAV vectors
For quantification of the surface-bound 6xHis AAV, viral genomic titers were determined 
by quantitative PCR. Surface-bound AAV vectors were incubated with cell-culture media 
without cell-seeding. At each time point, cell-culture medium was collected, and the surface 
was rinsed twice with PBS, which was also collected for quantification. Subsequently, viral 
vectors were quantified using QPCR. For quantification of the surface-dissociated 6xHis 
AAV, immobilized 25% 6xHis AAV vectors were incubated with cell-culture media without 
cell-seeding for each time point (4hrs, 1, 2, 4, 6 days). As with quantifying surface-bound 
AAV, both cell culture medium and rinsed buffers were collected at each time point, and 
viral vectors were quantified using QPCR.
Quantification of vector internalization
Viral vectors associated with cells were quantified to examine each delivery mechanism 
(bolus vs. substrate-mediated delivery). Note that percentages for each delivery mechanism 
were calculated from the initial quantities that were added to the medium (bolus) and to the 
surface for binding (substrate). After a 2, 4, or 8 day incubation at 37°C, the media were 
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removed, and the surface was rinsed twice with PBS. Cells were subsequently trypsinized 
and collected by centrifugation 20. To prevent the immediate association of surface-bound 
AAV vectors on the detached cells during the trypsinization, the cultures were incubated and 
blocked with heparin (30 µg/mL) at 37°C for 30 minutes prior to trypsinization. Vectors in 
the collected buffers were harvested and quantified using QPCR to estimate the amount of 
cell-internalized AAV vector.
Transduction assay
At several time points (2, 4, and 6 days), luciferase levels were measured using a 
luminometer (Turner Biosystems), which was set for a 2s delay with signal integration for 
10s, using the luciferase assay system (Promega, WI), with levels normalized to the total 
amount of protein, which was measured using a BCA™ Protein Assay Kit (Pierce, 
Rockford, IL). For bolus delivery, 107 genomic particles of wt AAV2 or 25% 6xHis AAV 
were directly added to the cell culture medium (5,000 cells / well).
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Figure 1. 
Schematic illustration of 6xHis AAV vectors and immobilization of the vectors onto the 
surface. (a): A view of the trimer at the 3-fold axis of symmetry in the capsid (Rasmol). The 
heparan sulfate proteoglycan (HSPG) binding site, where the 6xHis insertion occurs, is 
shaded in black. (b): Binding of 6xHis AAV vectors on Ni-NTA-biotin conjugated on the 
streptavidin surface.
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Figure 2. 
(a): Schematic illustration of 6xHis AAV vectors formed by varying the mass ratio of pHis 
to pXX2. (b): Surface-bound quantity of hexa-histidine tagged AAV as a function of both 
the concentration of biotin-NTA on the surface and the fraction of histidine residues on the 
viral surface. (c): the amount of 25% 6xHis AAV vectors dissociated from the surface 
containing no cells.
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Figure 3. 
(a): Quantification of vector internalization into cells after Ni-NTA surface mediated 
delivery or 25% 6xHis AAV or bolus delivery of vectors. (b): HEK293T cell infection and 
luciferase gene expression by substrate-bound AAV vectors, which were formulated with 
different ratios of pHis6/pXX2.
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Figure 4. 
Luciferase expression following substrate-mediated and bolus gene delivery. Luciferase 
expression for various cell types – including (a) HEK293T, (b) HeLa, (c) CHO, and (d) 
B16F10 cell lines – were investigated.
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